- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, April 12, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care® (AJMC®)'s coverage of the 2019 Community Oncology Conference. The article, “Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations,” covered a session that found while healthcare experts may agree that the shift from volume to value is well under way, the definition of value has a different answer depending who you ask. Tuesday’s newsfeed included an AJMC® interview with Daniel Ontaneda, MD, a neurologist at the Cleveland Clinic. During the interview, Ontaneda explained that there are 2 approaches for treating multiple sclerosis, and the DELIVER-MS study is the first to see which approach works better.
DocWire News’ article on generic drugs included the AJMC® published study “Consumer Attitudes and Factors Related to Prescription Switching Decisions in Multitier Copayment Drug Benefit Plans,” which surveyed patients and found that most respondents did not believe that formulary drugs were safer or more effective than nonformulary drugs, but 39.7% believed formulary drugs were relatively less expensive. Most patients indicated that they were willing to consider switching from a nonformulary drug to a formulary drug for a lower copayment.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More
